We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Kanabo Group Plc | LSE:KNB | London | Ordinary Share | GB00BYQCS703 | ORD 2.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.70 | 88,875 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.50 | 1.90 | 1.70 | 1.70 | 1.70 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 603k | -6.87M | -0.0109 | -1.56 | 10.75M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:24:08 | O | 1,773 | 1.56 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/3/2024 | 07:00 | UK RNS | Kanabo Group PLC Expansion of Treat It to Mental Health Treatments |
| 27/3/2024 | 17:12 | UK RNS | Kanabo Group PLC Holding(s) in Company |
| 25/3/2024 | 07:00 | UK RNS | Kanabo Group PLC Germany Medical Cannabis Legislation Reform |
| 18/3/2024 | 09:14 | UK RNS | Kanabo Group PLC Agritec Update |
| 15/1/2024 | 07:00 | UKREG | Kanabo Group PLC Partnership to launch a Walk-In Pain Clinic |
| 14/11/2023 | 07:00 | UKREG | Kanabo Group PLC Contract Extension With Major UK Retailer |
| 02/11/2023 | 07:00 | RNSNON | Kanabo Group PLC Partnership with BRITISH CANNABIS(TM) |
| 29/9/2023 | 07:00 | UKREG | Kanabo Group PLC Half-Year Results |
| 31/8/2023 | 11:13 | UKREG | Kanabo Group PLC Total Voting Rights |
| 11/8/2023 | 11:36 | UKREG | Kanabo Group PLC Issuance of New Ordinary Shares and TVR |
Kanabo (KNB) Share Charts1 Year Kanabo Chart |
|
1 Month Kanabo Chart |
Intraday Kanabo Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/3/2024 | 08:02 | Kanabo Group Medicinal Cannabis | 1,809 |
| 13/6/2023 | 09:22 | KANABO - Riding the Cannabis Wave | 22 |
| 25/2/2021 | 15:34 | Kanobo Warrants | 4 |
| 15/2/2021 | 13:05 | Kanabo Group Medicinal Cannabis | 2 |
| 17/8/2009 | 17:18 | Kinbauri Gold: Alive and Kicking | 26 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 27/4/2024 09:20 by Kanabo Daily Update Kanabo Group Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker KNB. The last closing price for Kanabo was 1.70p.Kanabo currently has 632,427,870 shares in issue. The market capitalisation of Kanabo is £10,751,274. Kanabo has a price to earnings ratio (PE ratio) of -1.56. This morning KNB shares opened at 1.70p |
Posted at 29/12/2023 11:31 by chica1 Hellenic Dynamics is a scam stay well away..Billions and Billions of shares outstanding.Kanabo has some hope with its GP Service division. A NHS contract would turn this share on its heels |
Posted at 17/7/2023 08:10 by oakridge Comment from the HELD thread on this RNS by KNB this morning:Oakridge17 Jul '23 - 07:49 - 1049 of 1049 Edit 0 1 0 An interesting RNS at KNB this morning that is worth comparing and contrasting with HELD. Their partly owned (40%) subsidiary, Agritec, has a contract to develop a cannabis production site in Spain. They are a predicted 24 months away (yes - approx two years away) from being able to produce 3000kg annually...of which they will only have a partial share.....and that's if all goes to plan. I suspect a soft response by the mkt. Their CEO is very upbeat about this however and believes it will deliver significant revenues and shareholder value. Whilst it is good news for their own supply chain, the above figure and time lines help bring some sweeping perspective as to just how large HELD *could* become and where we are in respect of timing... HELD's license is good for 55,000kg annually and a site that can be incrementally scaled to match the size of that license. The bunkers (already built) that HELD intends using first are good for 1000kg, with further expansion across the site via POD agreements, the first of which should be via Demecan.... We were recently told that we were on schedule for the first cropping this quarter and we were also told further PODS were in the pipeline..... KNB's apparent enthusiasm for their partly owned 3000kg in approx 24 months brings some useful contrast to where HELD apparently are, I feel. A lot can happen in two years, but its reassuring to think KNB are taking that route with a 24 month window, growing to that fairly limited scale and in a country that will likely have higher costs than Greece. A few checkpoints still to be cleared at HELD of course as well as the clean execution and sale of our first crop......but should that happen and we get to see POD agreements arriving and being implemented, I should think it will inspire the market somewhat. We'll see. AIMO ADYOR etc. |
Posted at 08/6/2023 17:29 by chica1 I think this is ripe for a large investment by a whale who has the money to invest in the 'docs on call'division.Its almost impossible to get an in person consult with a GP in a timely manner.You can't get an online company like that up on running on a shoestring. Current shareholders might have to take a bath considering the collapse in share price but at least management won't have to come back and tap shareholders every 6 months. Down the road a well capitalised Kanabo could and probably should be 2 different companies.There is still a stigma about the Cannabis industry even if it is for medical purposes. That being said it's still a very risky proposition! |
Posted at 07/6/2023 07:34 by the crypt Whichever way you look at it mr moronic sandwich muncher the company share price has gone down massively unless you got in at 2p. You only demonstrate what a massive useless tool that you are. So I will laff at you. |
Posted at 15/2/2023 23:26 by oakridge IMO, HELD most probably have superior cash reserves to KNB at this point in time.....plus HELD's cash burn rate will, in all likelihood, be somewhat lower than KNB's, both now and as HELD moves through the initial phase 1 cycle this year.I suggest you look carefully at KNB's interims: at where the money is going, in what kind of quantities and so on. It's not a criticism. I am just pointing to the demands of their business model and just what they are trying to do. HELD have stated on more than one occasion that the cash from their listing is more than sufficient to get to sales - scheduled as soon as late Q2. It is intended that expansion into Phase 1b and into Phase 2 will be done in line with mkt demand and funded by sales. As for marketing and distribution, firstly I'm not sure they need to market (much). And they are selling TO distributors (ie they are not distributors themselves). I think you have a fundamental misunderstanding of the business models of both companies and what each are and, are not, trying to do. Your earlier post trumpeting KNB's business model over HELD's apparent lack of one at all, confirms it. And once again, I see no reason to pit one company against the other as you are apparently so keen to do. They are trying to enter the market doing different things, albeit with some overlap in places, as I've previously pointed out. The business models are different. I am not saying one is better than the other but KNB's is certainly more complex to establish as they are aiming for vertical integration and ultimately, control over full supply chain, right down to CE certification and methods and points of delivery, not to mention prescription and opening up patient access. This is not something that can be done overnight and is potentially infinitely more capital intensive than HELD's phased approach of doing one thing well, over and over. Without good and ready suppliers of raw material, there is no industry. There is no primary care, no secondary care, no consultancy firms, no distributors, no vape R&D, no patents, no need for a CE and so on. Further out I'm sure HELD will want to become involved in genetic banking and contributing in some capacity to clinical trials, but they can be up and running and generating cash well before then.....just as the market currently demands. Demand for raw material is currently outstripping supply and that demand is rising sharply. HELD look like they are in with half a chance of contributing meaningfully to that supply and, on info available, being competitive to boot. Sure enough there are risks to both companies - some of which I'be mentioned in the past. But to pour scorn over one company - particularly for the REASONS you have - and to pit it against the other seems not only pointless but perhaps belies a fundamental misunderstanding of what each respective company is aiming to achieve. Who knows, KNB might end up being infinitely more successful - I'm open to that scenario - my bets are spread broadly - but it wont, imo, be for your reasoning. AIMO ADYOR NAI etc. |
Posted at 14/2/2023 17:56 by oakridge Currypasty, thank you for that.FWIW I agree with Tom on this point and posted fairly recently about KNB's cash burn and capital demands at this point in their evolution and made a comparison / contrast to HELD's relatively strong cash position and their respective time frames to meaningful cash generation. HELD's expenses *should* be relatively few at this stage, and what expenses they do have for the final fit-out of their facilities in Greece should be more than covered by their existing resources: they are funded through to at least first sales and, as the company has stated, they already have term sheets in place good for around a years growth / supply. They are also already in advanced discussions with other European distributors. KNB, if successful, should be Pan-European. HELD has the same ambition. The difference is, HELD's first revenues will come from the much more ready (and mature) market of Germany.....where as KNB are seeking traction, initially, in the UK. I don't begrudge KNB's need for capital and it's more of an observation, less a criticism. They are a small company, trying to do a lot. HELD are also a small company, but their business model is more focussed. As stated, I sliced KNB on the recent climb and effectively have a free carry.....adding to HELD in the meantime when I'm in the mood and whilst the price is just so suppressed. KNB are owed a decent sum of money, but no saying if or when that will come in and the H1 figures reveal a more than likely need for more money, sooner rather than later. Their 100% gain in primary care sales is welcome but of course it is coming off an extremely low base. And as you say, no mention of quantities, margins etc They are both interesting companies. Despite the weak start I do think HELD has significant potential over the next 18 - 24 months. We will know more in Q2 when they should start releasing initial sales figures as well as the scope of further supply contracts in mainland Europe. NAI ADYOR ETC |
Posted at 27/1/2023 10:50 by oakridge idlejack - you might well be correct re. HELD.I have now written pretty extensively about that stock and its current predicament....parti As I have tried to explain (perhaps unsuccessfully) to someone only last night: "you are wrong to automatically ASSUME that a falling share price in the meantime is necessarily bad news for those looking to build a position, add or enter the fray". The weakness at HELD will certainly be uncomfortable for those who are 'all in' and who are in any way unsure about their investment rationale or timelines. But for those who have some form of confidence in the business, or at least believe in the narrative that it will soon be cash generative and meaningfully so, the current weakness and seller in the mkt could be seen as presenting something of an opportunity - especially for those with dry powder. HELD carries risk and uncertainty of course and is in no way a guaranteed winning ticket (at any price). KNB, due to its earlier arrival (launching into the heady highs of the cannabis sentiment) and relatively slow progress since, is somewhat more advanced along the 'curve of disappointment'..... It goes entirely against human nature to be drawn to weak share prices and poor sentiment and especially because of the woeful year many cannabis stocks have just had specifically, there is likely to be more than a little cynicism washing around in the space. However I believe 2023 will be the year where some confidence returns to the sector as a whole. As ever, it will be about picking the right ones for the right reasons and at the right prices. AIMO and ADYOR. |
Posted at 26/1/2023 11:20 by wageslave HELD is tanking today. Perhaps that's impacting on KNB share price. |
Posted at 26/1/2023 08:31 by oakridge I should have added...we are looking at HELD on an 18 - 24 month view and as for KNB we will be interested to assess how they have faired come the end of 2023 and if they manage to achieve any breakthrough sales via the recent products they announced.Their new routes to market for those same products are of course largely untested...and the current share price here tells you as much. But what is interesting perhaps is the fact that they are on the verge of addressing the medicinal side of the domestic market - which is currently underserved - and where T/O and margins should be infinitely more attractive than the CBD / Lifestyle wing of the company (which is of little interest to us). News on first sales of those products undertaken with LYPHE via Dispensary Green should hopefully shift perception and mkt sentiment of KNB, in a domestic setting which is slightly lagging behind the overall curve seen in Europe. The second route to market (via The GP Sevice) is similarly untested, but any penetration here will prove to the market that they have successfully implemented a sales channel that can be rolled out and further expanded. There are around 17,000 patients receiving medicinal THC in the UK and the findings in the reports (due March) may have implications in regards to the NHS' involvement and indeed the broader acceptance and adoption of practitioners in the private sector. All in all it is shaping up to be a pivotal year for the space. The CEO has stated that one of the biggest challenges is obtaining sufficient and consistent quantities of clinical grade material. From that perspective their investment in HELD is interesting. AIMO etc. |
Posted at 26/1/2023 07:50 by oakridge A good rise off the recent lows here yesterday and supported by the third largest upswing in volume since early 2021.We have watched KNB from the sidelines for well over a year and since around the time of their strategic investment into Hellenic Dynamics (HELD), which came to market in early December '22 via an RTO and only after a protracted period of regulatory approval. As peeps here should all know, HELD are cultivators with facilities in located in Greece who are targeting the European market, including the UK, with term sheets already signed for supply into Germany. Initial sales are anticipated in Q2 of this year. We already hold some shares in HELD but are trying to build a meaningful position there during the current phase of weakness in the share price. This has been aided by a seller in the market together with the likely leave of 'legacy holders' (ie those who were invested in an unrelated company prior to the suspension and RTO), and who are perhaps not aligned with the resulting company and its future. We have also, finally, become recent and modest buyers of KNB. Aside from KNB's material interest in HELD, the two companies have both some differentiation and overlap. KNB listed into a period of great enthusiasm in respect of the THC space whilst HELD, due to regulatory hurdles and delays surrounding its pioneering status as first cultivator with a main listing, was much later in its arrival. This delay has been a mixed blessing. Whilst the space cooled considerably in 2022, the future and underlying demand for medicinal cannabis, at this stage at least, appears to have only strengthened. Many other THC stocks reveal a similar woeful 2022 to that of KNB, trading at a mere fraction of where they were when medicinal cannabis was very much the darling of the moment. The space is still early stage and, in my view, underserved in that it is still very much evolving and defining itself (both on the regulatory front and in terms of adoption and acceptance). There are now 25 countries in the EU who allow THC dominant medical prescriptions and that number has grown only very recently and continues to grow. In the UK specifically (which sees one of the worst opioid addiction/dependence issues Europe) the market for THC grew by 425% in 2021 alone. The predicted growth rates for Germany over the next five years - a comparatively mature, but still very early stage market - are also impressive. The space is certainly not without its challenges and obstacles, but whilst many cannabis stocks have had an extremely poor 2022, the actual space itself would seem undiminished. Therefore I think as things open up, and by that I mean through greater adoption and the potential for supportive clinical findings (we are due some in the UK specifically in March) we may begin to see some disconnect emerge between market traction and company valuations and potential. I will continue to monitor both companies and it will be interesting to see if 2023 is the year which sees a welcome return of favour to this sector as a whole. I think there's a reasonable chance that's on the cards. AIMO only and NAI. ADYOR etc. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
